The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 661-670

  Srirangam, Anjaiah ^a   Milani, Monica ^a   Mitra, Ranjana ^a   Guo, Zhijun ^a   Rodriguez, Mariangellys ^a   Kathuria, Hitesh ^b   Fukuda, Seiji ^b,c   Rizzardi, Anthony ^d   Schmechel, Stephen ^d   Skalnik, David G ^b   Pelus, Louis M ^b,c   Potter, David A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Non small cell lung cancer; Ritonavir; Survivin

Indexed keywords

CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GEMCITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; K RAS PROTEIN; MESSENGER RNA; PROTEIN P53; RITONAVIR; RNA; STAT3 PROTEIN; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; LUNG ADENOCARCINOMA; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 79953025303     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820c9e3c     Document Type: Article

References (60)

1. Chong CR, Xu J, Lu J, et al. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2007;2:263-270. (Pubitemid 47629214)
2. Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004;64:7426-7431. (Pubitemid 39372084)
3. Srirangam A, Mitra R, Wang M, et al. Effects ofHIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Can-cer Res 2006;12:1883-1896.
4. Kumar S, Bryant CS, Chamala S, et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer 2009;8:26.
5. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002; 99:3771-3779. (Pubitemid 34534550)
6. Laurent N, de Bouard S, Guillamo JS, et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 2004;3:129-136. (Pubitemid 39193687)
7. Kren L, Brazdil J, Hermanova M, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carci-nomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004;12:44-49. (Pubitemid 38332319)
8. Ai Z, Yin L, Zhou X, et al. Inhibition of survivin reduces cell prolifer-ation and induces apoptosis in human endometrial cancer. Cancer 2006;107:746-756. (Pubitemid 44232667)
9. Song J, So T, Cheng M, et al. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005;22: 621-631. (Pubitemid 40719197)
10. Fukuda S, Foster RG, Porter SB, et al. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 2002;100:2463-2471.
11. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000;19:3225-3234. (Pubitemid 30487409)
12. Zhao J, Tenev T, Martins LM, et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000;113:4363-4371. (Pubitemid 32000697)
13. Ambrosini G, Adida C, Altieri DC A novel anti-apoptosis gene, sur-vivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921. (Pubitemid 27353455)
14. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-134. (Pubitemid 30064984)
15. Altieri DC Survivin, cancer networks and pathway-directed drug dis-covery. Nat Rev Cancer 2008;8:61-70.
16. Shinohara ET, Hallahan DE, Lu B. The use of antisense oligonucleotides in evaluating survivin as a therapeutic target for radiation sensitization in lung cancer. Biol Proced Online 2004;6:250-256. (Pubitemid 41358141)
17. Pennati M, Binda M, Colella G, et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. JInvest Dermatol 2003;120:648-654. (Pubitemid 36344009)
18. Wang Y, Zhu H, Quan L, et al. Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther 2005;4:974-978. (Pubitemid 41598593)
19. Song H, Xin XY, Xiao F, et al. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol 2008;136:83-89.
20. Asanuma K, Kobayashi D, Furuya D, et al. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 2002;93: 1057-1062. (Pubitemid 35154273)
21. Schimmer AD, Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology Am Soc Hematol Educ Program 2005;215-219.
22. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009;35:553-562.
23. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003;200:620-626. (Pubitemid 36987311)
24. Karczmarek-Borowska B, Filip A, Wojcierowski J, et al. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 2005;43:237-242. (Pubitemid 41582146)
25. Fan J, Wang L, Jiang GN, et al. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 2008;61:91-96.
26. Dasgupta P, Kinkade R, Joshi B, et al. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci USA 2006;103:6332-6337.
27. Morgillo F, Woo JK, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006;66:10100-10111. (Pubitemid 44672064)
28. Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007;13:2795-2803. (Pubitemid 46788049)
29. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancercells to chemotherapy. Cancer Res 2000;60:2805-2809. (Pubitemid 30395796)
30. Dewan MZ, Uchihara JN, Terashima K, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 2006;107:716-724. (Pubitemid 43076398)
31. Mazurenko NN, Kogan EA, Zborovskaya IB, et al. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 1992;28:372-377.
32. Song L, Turkson J, Karras JG, et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-4165. (Pubitemid 36876236)
33. Dalwadi H, Krysan K, Heuze-Vourc'h N, et al. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 2005; 11:7674-7682. (Pubitemid 41611609)
34. Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-376. (Pubitemid 47339214)
35. Kato T, Ieki R, Saito E, et al. A long-term survival case of small cell lung cancer in an HIV-infected patient. Jpn J Clin Oncol 2005;35:349-352. (Pubitemid 41444284)
36. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemo-radiation for locally advanced pancreatic cancer. J Clin Oncol 2008;26: 2699-2706.
37. Okuma Y, Hosomi Y, Takagi Y, et al. Long-term survival following metachronous intratumoral hemorrhage in an HIV-infected patient with lung cancer. Int J Clin Oncol 2010;15:515-518.
38. Zhang YW, Jones TL, Martin SE, et al. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem 2009;284:18085-18095.
39. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209. (Pubitemid 27122520)
40. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-6164. (Pubitemid 35244466)
41. Makinson A, Pujol JL, Le Moing V, et al. Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol;5:562-571.
42. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
43. Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999;17:2190-2197. (Pubitemid 29318852)
44. Fogli S, Danesi R, De Braud F, et al. Drug distribution and pharmaco-kinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol 2001;12:1553-1559. (Pubitemid 34065884)
45. Schiller JH, Harrington D, Belani CP, et al. Comparison of four che-motherapy regimens for advanced non-small-cell lung cancer. N Engl JMed 2002;346:92-98. (Pubitemid 34438899)
46. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-414.
47. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. Aids 1999;13:2083-2089. (Pubitemid 29509585)
48. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Anti-microb Agents Chemother 1997;41:898-905. (Pubitemid 27194157)
49. Bao R, Connolly DC, Murphy M, et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002;94: 522-528. (Pubitemid 34411291)
50. Ulukus EC, Kargi HA, Sis B, et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Appl Im-munohistochem Mol Morphol 2007;15:31-37. (Pubitemid 46673313)
51. Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res 2008;68:7947-7955.
52. Wachters FM, van Putten JW, Maring JG, et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-562. (Pubitemid 37040953)
53. Crul M, van Waardenburg RC, Bocxe S, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003;65:275-282. (Pubitemid 36015830)
54. Jiang G, Ren B, Xu L, et al. Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res 2009;29:223-228.
55. Dantzer F, Ame JC, Schreiber V, et al. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 2006;409: 493-510.
56. Dianova II, Sleeth KM, Allinson SL, et al. XRCC1-DNA polymerase beta interaction is required for efficient base excision repair. Nucleic Acids Res 2004;32:2550-2555. (Pubitemid 38854807)
57. Moser J, Kool H, Giakzidis I, et al. Sealing ofchromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol Cell 2007;27:311-323. (Pubitemid 47058307)
58. Zhu G, Lippard SJ. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry 2009;48:4916-4925.
59. Guggenheim ER, Xu D, Zhang CX, et al. Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. Chembiochem 2009;10:141-157.
60. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhi-bition, gemcitabine, and cisplatin. Cancer Res 2010;70:7970-7980.